(HealthDay)—Vimizim (elosulfase alfa) has been approved by the U.S. Food and Drug Administration to treat a rare childhood disorder called Mucopolysaccharidosis Type IVA, also known as Morquio A syndrome.
Feb 17, 2014
0
0
A novel drug is being touted as a major step forward in the battle against Australia's escalating rates of obesity and associated metabolic diseases. As it stands, 2 in 3 adults in Australia are classified as being overweight ...
Aug 21, 2018
0
3
Researchers in Calgary have launched the first gene therapy clinical trial in the world for Fabry disease, a rare inherited enzyme deficiency that can shorten the lifespan of people who have it by as much as 40 years.
Jan 24, 2013
0
0
By uncovering the 3-dimensional structure of an enzyme that is critical for the survival of the bacterium that cause tuberculosis, researchers may be one step closer to developing a new strategy to combat TB infections.
Feb 17, 2016
0
0
Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear ...
Jun 24, 2013
0
0
Ribonucleotide reductase (RR) is a target metabolic enzymes for cancer therapy. Few studies have described the correlation between RRM2 and the development of colorectal cancer. And the possible mechanism by which RRM2 mediates ...
Sep 18, 2012
0
0
On good days, the immune system can effectively handle pathogens that invade the body. However, when foreign matter takes the upper hand, the body builds a wall of immune cells called granuloma around the pathogens to isolate ...
Dec 7, 2023
0
0
"Childhood" and "dementia" are two words we wish we didn't have to use together. But sadly, around 1,400 Australian children and young people live with currently untreatable childhood dementia.
Apr 26, 2024
0
1
